文献速递炎症性肠病肝病消化道肿瘤与早癌

原发性硬化性胆管炎对炎症性肠病患者癌症与死亡风险的影响:基于性别、种族和年龄的分析

Effects of Primary Sclerosing Cholangitis on Risks of Cancer and Death in People With Inflammatory Bowel Disease, Based on Sex, Race, and Age.
PubMed 文献 · Gastroenterology · 2020-05-20

一项基于英格兰全国健康登记数据的10年队列研究,纳入284,560例新发炎症性肠病(IBD)患者,其中2,588例合并原发性硬化性胆管炎(PSC)。研究发现PSC-IBD患者相比单纯IBD患者,结直肠癌、肝胆胰癌及全因死亡风险显著增加,且风险因性别、种族和诊断年龄而异。

要点

  • PSC-IBD患者结直肠癌风险增加(HR 2.43),诊断年龄<40岁者风险更高。
  • PSC-IBD患者肝胆胰癌风险显著增加,其中胆管癌HR 28.46。
  • 诊断PSC时年龄<40岁、男性及非洲加勒比裔患者PSC相关事件风险更高。

核心结论

  • PSC-IBD患者相比单纯IBD患者,结直肠癌、肝胆胰癌和死亡风险均显著增加。
  • IBD诊断年龄<40岁的PSC-IBD患者结直肠癌和全因死亡风险高于晚发患者。
  • 诊断PSC时年龄<40岁、男性及非洲加勒比裔患者PSC相关事件发生率更高。

研究设计与样本

  • 基于英格兰全国健康登记数据的10年队列研究,纳入2006年4月至2016年4月新诊断的284,560例IBD患者,随访至2019年4月。
  • 其中2,588例患者合并PSC(PSC-IBD),其余为单纯IBD。

主要发现

  • PSC-IBD患者死亡风险HR 3.20,结直肠癌风险HR 2.43(P < .001),结直肠癌诊断中位年龄59岁 vs 69岁(P < .001)。
  • PSC-IBD患者胆管癌HR 28.46,肝细胞癌HR 21.00,胰腺癌HR 5.26,胆囊癌HR 9.19(P < .001)。
  • 诊断PSC前接受年度影像学检查的患者,肝胆胰癌相关死亡风险较低(HR 0.43;P = .037)。
  • PSC-IBD患者中,诊断PSC时年龄<40岁者PSC相关事件或肝移植占临床事件的约75%,而>60岁者占31%(P < .001)。
  • 非洲加勒比裔相比白人,肝移植或PSC相关死亡风险增加(HR 2.05;P < .001);女性风险降低(HR 0.74;P = .025)。

关键数值与推荐

  • IBD诊断年龄<40岁的PSC-IBD患者结直肠癌风险是单纯IBD患者的4倍;>60岁诊断IBD者两组无差异。
  • 年龄<40岁组PSC-IBD与单纯IBD的死亡率差异最大(发生率比>7),>60岁组<1.5。

临床怎么用

  • 对PSC-IBD患者应加强结直肠癌和肝胆胰癌监测,尤其年轻诊断IBD者。
  • 年度影像学检查可能降低PSC-IBD患者肝胆胰癌相关死亡风险。
  • 关注男性、非洲加勒比裔及年轻诊断PSC患者的PSC相关事件风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: There are insufficient population-level data on the effects of primary sclerosing cholangitis (PSC) in patients with inflammatory bowel disease (IBD). METHODS: We identified incident cases of IBD, with PSC (PSC-IBD) and without, from April 2006 to April 2016 and collected data on outcomes through April 2019. We linked data from national health care registries maintained for all adults in England on hospital attendances, imaging and endoscopic evaluations, surgical procedures, cancer, and deaths. Our primary aim was to quantify the effects of developing PSC in patients with all subtypes of IBD and evaluate its effects on hepatopancreatobiliary disease, IBD-related outcomes, and all-cause mortality, according to sex, race, and age. RESULTS: Over 10 years, we identified 284,560 incident cases of IBD nationwide; of these, 2588 patients developed PSC. In all, we captured 31,587 colectomies, 5608 colorectal cancers (CRCs) 6608 cholecystectomies, and 41,055 patient deaths. Development of PSC was associated with increased risk of death and CRC (hazard ratios [HRs], 3.20 and 2.43, respectively; P < .001) and a lower median age at CRC diagnosis (59 y vs 69 y without PSC; P < .001). Compared to patients with IBD alone, patients with PSC-IBD had a 4-fold higher risk of CRC if they received a diagnosis of IBD at an age younger than 40 years; there was no difference between groups for patients diagnosed with IBD at an age older than 60 years. Development of PSC also increased risks of cholangiocarcinoma (HR, 28.46), hepatocellular carcinoma (HR, 21.00), pancreatic cancer (HR, 5.26), and gallbladder cancer (HR, 9.19) (P < .001 for all). Risk of hepatopancreatobiliary cancer-related death was lower among patients with PSC-IBD who received annual imaging evaluations before their cancer diagnosis, compared to those who did not undergo imaging (HR, 0.43; P = .037). The greatest difference in mortality between the PSC-IBD alone group vs the IBD alone group was for patients younger than 40 years (incidence rate ratio >7), in contrast to those who received a diagnosis of IBD when older than 60 years (incidence rate ratio, <1.5). Among patients with PSC-IBD we observed 173 first liver transplants. Liver transplantation and PSC-related events accounted for approximately 75% of clinical events when patients received a diagnosis of PSC at an age younger than 40 years vs 31% of patients who received a diagnosis when older than 60 years (P < .001). African Caribbean heritage was associated with increased risks of liver transplantation or PSC-related death compared with white race (HR, 2.05; P < .001), whereas female sex was associated with reduced risk (HR, 0.74; P = .025). CONCLUSIONS: In a 10-year, nationwide study, we confirmed that patients with PSC-IBD have increased risks of CRC, hepatopancreatobiliary cancers, and death compared to patients with IBD alone. In the PSC-IBD group, diagnosis of IBD at age younger than 40 years was associated with greater risks of CRC and all-cause mortality compared with diagnosis of IBD at older ages. Patients who receive a diagnosis of PSC at an age younger than 40 years, men, and patients of African Caribbean heritage have an increased incidence of PSC-related events.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Trivedi PJ, Crothers H, Mytton J, et al. Effects of Primary Sclerosing Cholangitis on Risks of Cancer and Death in People With Inflammatory Bowel Disease, Based on Sex, Race, and Age. Gastroenterology. 2020. PMID: 32445859. doi:10.1053/j.gastro.2020.05.049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。